Cytokinetics (NASDAQ:CYTK) & Gain Therapeutics (NASDAQ:GANX) Head-To-Head Review

Cytokinetics (NASDAQ:CYTK) and Gain Therapeutics (NASDAQ:GANX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends and analyst recommendations.

Volatility and Risk

Cytokinetics has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500.

Valuation & Earnings

This table compares Cytokinetics and Gain Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$67.67 million	116.64	-$784.96 million	($7.22)	-8.79
Gain Therapeutics	$50,000.00	1,152.10	-$20.16 million	($0.50)	-2.64

Gain Therapeutics has lower revenue, but higher earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

12.0% of Gain Therapeutics shares are held by institutional investors. 2.6% of Cytokinetics shares are held by insiders. Comparatively, 4.2% of Gain Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings for Cytokinetics and Gain Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1	1	18	0	2.85
Gain Therapeutics	1	0	4	0	2.60

Cytokinetics presently has a consensus target price of $105.44, suggesting a potential upside of 66.24%. Gain Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 480.81%. Given Gain Therapeutics’ higher probable upside, analysts clearly believe Gain Therapeutics is more favorable than Cytokinetics.

Profitability

This table compares Cytokinetics and Gain Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-1,321.12%	N/A	-51.01%
Gain Therapeutics	N/A	-161.59%	-118.36%

Summary

Gain Therapeutics beats Cytokinetics on 8 of the 14 factors compared between the two stocks.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

About Gain Therapeutics

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.